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Akut lenfoblastik lösemili adolesan bir kız çocukta her iki diz ve sağ topukta osteonekroz
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Abstract
Although rare, avascular necrosis of bone is a serious and incapacitating complication seen in children with acute lympho-
blastic leukemia receiving high dose steroids. Here we present a 16 year-old girl who developed bilateral knee and right 
ankle avascular osteonecrosis one year after intensive chemotherapy for medium risk acute lymphoblastic leukemia. 
Indirect curettage of necrotic tissue and bone grafting were performed for both knees whereas conservative measures had 
been sufficient for the ankle. Early recognition of this condition is important in prevention of disabling sequela in skeletal 
system. (Turk J Hematol 2009; 26: 34-7)
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Özet
Yüksek doz steroid tedavisi alan akut lenfoblastik lösemili çocuklarda avasküler kemik nekrozu ender ancak ciddi ve 
sakatlık bırakan bir komplikasyondur. Orta risk akut lenfoblastik lösemi için yoğun kemoterapi alan ve her iki diz ve sağ 
topukta avasküler osteonekroz gelişen 16 yaşında bir kız hasta sunulmuştur. Her iki diz nekrotik dokunun küretajı ve kemik 
grefti ile tedavi edilirken, topukta konservatif tedavi yeterli olmuştur. İskelet sisteminde sekel bırakabilen bu durumun erken 
tanınması önemlidir. (Turk J Hematol 2009; 26: 34-7)
Anahtar kelimeler: Akut lenfoblastik lösemi, avasküler osteonekroz, çocukluk çağı
Geliş tarihi: 09 Haziran 2008  Kabul tarihi: 02 Kasım 2008
Introduction
Avascular osteonecrosis (AON) is characterized by par-
tial loss of the bone. It is often seen as a complication of 
long term use of high dose steroids in children with acute 
lymphoblastic leukemia (ALL), other malignant tumors and 
even in healthy children [1-3]. Its incidence varies between 
1.09 % and 16 % in different series of children with ALL, 
though radiological incidence is even three times more 
common in asymptomatic children with ALL [3-8]. Clinical 
manifestations resemble those of leukemic infiltration of the 
bone. We here report a case of severe AON in both knees 
and right ankle occurring during maintenance chemothera-
py in an adolescent girl with ALL. Case
A 16 year-old girl was admitted with a three weeks history 
of fever, fatigue, pallor, generalized lymphadenopathy and 
bulky hepatosplenomegaly. She had pancytopenia (Hb:  8.2 g/
dl, WBC: 1670/mm3, platelet count: 15200/mm3). Pre-B ALL 
was diagnosed (CD 10, 19, 22, 45, cyIgM, HLA-DR positive) 
with 97% blasts in the bone marrow. T (4; 11) and t (9; 22) by 
RT-PCR was negative. With ALL-BFM 95 treatment protocol 
prednisone good response and complete remission were 
observed on days 8 and 33 respectively. During remission 
induction, she had sinus aspergillosis which was successfully 
treated with liposomal amphotericin B for 4 weeks, followed by 
itraconazole for 3 weeks. She also developed vincristine neu-
rotoxicity during itraconazole treatment that caused the dis-
continuation of itraconazole. Prophylactic ciprofloxacin was 
given during neutropenic periods. Two years after diagnosis 
while on maintenance therapy, she developed pain in both 
knees that forced a negative search for relapse. Intensity of 
bone pain gradually increased especially after long term stand-
ing and walking over the next 5 months. Two months after 
completion of maintenance chemotherapy, a magnetic reso-
nance imaging (MRI) was performed due to acute hyperemia 
and swelling in both knees which showed diffuse medullar 
pathological signal in 1/3 distal femur and 1/3 proximal tibia, 
consistent with avascular osteonecrosis (Figure 1a, b). 
Arthroscopical examination of both knees revealed a wide 
osteochondritis dissecans of both medial femoral condyles 
however, articular cartilage was not completely separated. 
Indirect curettage of bony necrotic tissue (forage) and bone 
grafting were performed in both femoral condyles. Pathologic 
examination of resected specimen, confirmed the diagnosis of 
AON (Figure 2). Immediately after operation, passive motion 
exercises were started and weight bearing was not allowed for 
one month in order to provide graft healing. Six months later, 
she had severe pain in the right ankle due to another osteone-
crotic focus in the medial section of talus (Figure 1c) which was 
treated with conservative measures including rest, avoidance of 
long and strenuous walks, refraining from weight gain. After two 
years off chemotherapy she is now well and could easily walk 
without limping only with a slight pain left in the right ankle.
Discussion
While late complications and impairment in quality of life 
due to chemotherapy have been largely studied, deleterious 
side effects of therapy on musculoskeletal system like pain, 
bone marrow edema, acute osteonecrosis, fractures, disability 
to move, deformation or loss of mineralization has encountered 
less attention [9]. Although the frequency and time of occur-
rence of these is not well identified the best reported is the 
incidence of AON being between 1.09% and 16% in different 
series of children with ALL and mostly occurring 3-5 years after 
diagnosis [3-8]. AON is more common in children over 10 
years and in girls, largely in weight bearing joints however 
clinical features are extremely variable ranging from asymptom-
atic patients to limping. Our patient was an adolescent girl who 
developed bilateral AON in both knees towards the end of 
maintenance chemotherapy and later in right talus. AON 
manifested itself initially as mild bone pain and tenderness over 
the involved areas and progressed rapidly to cause inability to 
walk. The time interval passed from the first mild pain to the 
severe incapacitating walking disability was only 5 months. 
Bone marrow and detailed radiological examinations should be 
done to distinguish leukemic relapse as clinical findings are 
similar. MRI is an easy and sensitive tool which recognizes 
AON by the characteristic low intensity signal demarcation 
consistent with bone infarction [9, 10]. It could also differentiate 
AON from leukemic relapse with 90 % accuracy with the later 
through multiple, well-defined nodular lesions [11]. 
Pathogenesis of AON is not well known. It seems to be a 
complex pathological process involving, suppression of osteo-
blasts, osteocyte apoptosis, and mechanical obstruction due 
to thromboembolism in sinusoidal vessels. When resorption of 
subchondral bone around necrotic area deteriorates the bony 
architecture, sustained pressure of the body weight and motion 
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Figure 1. T1 (a) and T2 (b)-weighed images of the knee reveals geog-
raphism that is the decreased signal intensity on T1-weighed images 
(black arrows) and increased signal on T2-weighed images (white 
arrows) typical for acute osteonecrosis. Increased signal intensity with 
geographic pattern in the talar head and distal tibia (black arrows) in 
T2 weighed images of the ankle joint 
Figure 2. Bone marrow necrosis with associated osteonecrosis-tumor 
cells appearing as eosinophilic cell ghosts and empty lacunae in bony 
trabeculae with loss of osteocytes (Hematoxylin-eosin, x 200)lead to bone fracture and collapse of the adjacent articular 
cartilage [9]. Steroids have been shown to increase apoptosis 
in osteocytes and association of AON with prolonged adminis-
tration along with high dose steroid therapy suggests that it 
may have a role in the development of this complication in 
children with ALL [3, 8, 9]. Comparing steroid doses in different 
ALL trials reveal that when total steroid dose is higher, bone 
morbidity like AON become more prevalent [3, 12]. Strauss et 
al also pointed out the potentially more toxicity of dexametha-
sone on the skeletal system compared to prednisone [12]. 
However there is evidence that shows steroids used as an anti-
emetic agent in cancer patients can also cause AON [13]. Our 
patient was the only symptomatic case of AON among our 82 
patients (25 of them were over 10 years of age) treated with the 
same ALL BFM-95 protocol which consists of 1837 mg/m2 
steroid as prednisone in induction, dexamethasone 236 mg/m2 
in reinduction, and 252 mg/m2 during maintenance of leukemia 
therapy (total steroid dose 5091.96 mg/m2 as prednisone; 
1mg dexamethasone=6.67 mg prednisone). Despite high risk 
patients (n:15) received additional 1841.16 mg/m2 steroid as 
prednisone, no symptomatic AON was observed within that 
group. Other chemotherapeutic drugs or antimicrobials like itra-
conazole which is known to inhibit the metabolism of cortico-
steroids might have increased the adverse effects of steroids on 
bone and therefore might have contributed to the pathogenesis 
of AON in our patient. 
In selected high risk patients, prophylactic use of fluoroqui-
nolones is suggested to reduce the incidence of Gram-negative 
bacteriemias. Ciprofloxacin which has been the principal qui-
nolone used in pediatrics has been reported to have musculo-
skeletal adverse effects like arthropathies [14, 15]. Although it 
causes cartilage damage in juvenile animal models and in 
necropsy materials of adults there is no evidence that it causes 
AON in children [15]. Furthermore, imaging and histopatho-
logical appearance of ciprofloxacin induced cartilage abnor-
malities is different from AON. 
Susceptibility of AON in pediatric ALL could suggest a role 
for genetic discrepancy. Van Beek et al studied the role of lipid 
metabolism however no contribution to an increased risk of 
AON was found [16]. Although not found in a small number of 
patients [5] presence of MTHFR 677T allele might also be 
searched as a risk factor for AON in pediatric ALL like it was in 
sickle cell disease [17]. 
It is shown that, at the end of one year therapy containing 
high cumulative doses of steroids 15% of ALL patients even 
without any clinical symptoms have changes in MRI consistent 
with AON. Although most of these patients could complete the 
scheduled therapy without progressive joint damage, patients 
with severe pain and earlier changes in MRI might require 
modification of treatment [10]. In this regard, although some 
groups suggest routinely screening certain joints that are sus-
ceptible to AON under chemotherapy, timely performance of 
MRI for early diagnosis seems more feasible.  
Early onset and severity of symptoms might determine both 
modification of causative drug therapy and alternatives of treat-
ment to heal AON. Chollet et al replaced steroids by metho-
trexate in patients with ALL who had AON of the ankle and 
observed significant regression of the lesions [18]. However in 
another study in which interval between diagnosis of malig-
nancy and AON was 16 months, therapy was not changed in 
any of the ALL patients with AON owing to completion of the 
steroid containing part of the treatment [19]. Our patient did 
not need any modification of chemotherapy since AON diagno-
sis was made after the chemotherapy was stopped. 
Healing treatment options of AON are based on the sever-
ity of the disease. Asymptomatic patients might just be 
observed whereas children with pain need medical interven-
tions such as limiting the physical activity, avoiding weight gain 
and using analgesic drugs. The multipotentiality of stem cells 
lead investigators to inject autologous marrow into the lesions 
which has been reported to have promising results like slowing 
the disease progression [9]. Other non-pharmacological proce-
dures like electrical stimulation, hyperbaric oxygen, administra-
tion of low molecular weight heparin have also been encoun-
tered in small groups of patients being mostly ineffective in 
steroid related disease. Surgery is suggested only when con-
servative therapies fail. Our patient had surgical intervention for 
the knees however conservative treatment had been adequate 
for the ankle. 
In conclusion, symptomatic AON, is an increasingly recog-
nized side effect of intensive chemotherapy in childhood ALL 
and must be kept in mind when a patient develops bone pain. 
While dealing with leukemia, in the case of bone pain, the very 
first suspicion is the disease relapse which prompts the physi-
cian to search for it. Nevertheless, it is substantial to employ 
other diagnostic options in the case of no relapse especially 
when there are symptomatic joints. AON can be regarded as 
the invisible part of iceberg since the incidence of asymptom-
atic cases is much higher than symptomatic ones. 
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